Grant of Share Options and Notification of Director / PDMR Dealings
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Group's Remuneration Committee and the Board have approved the grant of 500,000 options ("New Options") over ordinary shares of 4 pence each ("Ordinary Shares") to Jeremy Millard, Non-Executive Director, pursuant to the Group's existing share option schemes.
All New Options were granted with an exercise price of 10 pence each, being the closing middle market price on 29 November 2019. The New Options will vest over three years, one third vesting on each anniversary of the grant date.
The grant of 500,000 New Options equates to 0.33 per cent. of the Group's current issued share capital. In total, 9,420,406 options are now under grant but not exercised, which equates to 6.3 per cent. of the Group's current issued share capital.
The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation is appended below.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
Details of the person discharging managerial responsibilities/person closely associated
Reason for the notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Omega Diagnostics Group Plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument:
Ordinary Shares of 0.5 pence each
Nature of the transaction:
Grant of options over Ordinary Shares
Price(s) and volume(s):
· Aggregated volume:
Single transaction as in 4 c) above
Date of the transaction:
2 December 2019
Place of the transaction:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...